Total Funding
26
Total FundingPost-IPO Equity raised
Growth Score
pts
Heat Score
-6 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
195952
Ignyta is a biotechnology company catalyzing personalized medicine in autoimmune diseases.
James L. Freddo: DirectorPast Role: Anadys Pharmaceuticals, Chief Medical Officer and Senior Vice President, Drug Development
Robert Shoemaker: Director of BioinformaticsPast Role: Illumina, Scientist
About the Company
Ignyta is a scientifically-driven biotechnology company catalyzing personalized medicine in autoimmune diseases. Their goal is to revolutionize the quality of biomarkers and tests available to rheumatologists and patients to help them make better informed, more individualized treatment decisions; and to identify truly novel autoimmune disease
targets for biopharmaceutical companies to enable the development of precise therapies for patients worldwide.
Ignyta was incorporated in 2011 and operates in San Diego, California.
